» Articles » PMID: 21088848

Comparison of Muscle Ultrastructure in Myasthenia Gravis with Anti-MuSK and Anti-AChR Antibodies

Overview
Journal J Neurol
Specialty Neurology
Date 2010 Nov 20
PMID 21088848
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with myasthenia gravis (MG) with antibodies to muscle-specific receptor tyrosine kinase (MuSK) differ from acetylcholine receptor (AChR)-positive MG patients, as they frequently present with severe oculobulbar muscle weakness or with neck, shoulder, and respiratory muscle involvement. The neuromuscular junction (NMJ) has been confirmed to be the main target of both AChR- and MuSK-MG. However, histopathological investigation disclosed that muscle fiber atrophy was prevalent in AChR-MG, whereas mild myopathic changes and mitochondrial abnormalities were more frequently observed in MuSK-MG. As the pathogenetic mechanism in MuSK-MG remains unclear, this study investigated the submicroscopic pattern of muscle histopathology to establish a possible correlation between clinical involvement and subcellular morphological findings. Muscle biopsies from seven MuSK-MG patients and from seven patients with AChR-MG were analyzed by transmission electron microscopy. Myopathic and mitochondrial abnormalities were more prominent in MuSK-MG and show giant, swollen, and degenerated mitochondria with fragmented cristae. The most common changes in AChR-MG muscles were fiber atrophy, myofibrillar disarray, and Z-line streaming, consistent with mild neurogenic abnormalities. A different pathogenetic mechanism is emerging in MuSK-MG compared to AChR-MG. Mitochondrial abnormalities seem to be more prominent in MuSK-MG, whereas neurogenic atrophy is observed in AChR-MG.

Citing Articles

Relationship between fatigue and quantitative electromyography findings in patients with myasthenia gravis.

Savasci D, Mercan M, Yayla V Heliyon. 2024; 10(20):e39231.

PMID: 39640692 PMC: 11620218. DOI: 10.1016/j.heliyon.2024.e39231.


Mitochondrial dysfunction in myasthenia gravis: Exploring directions for future immunotherapy? A review.

Chen J, Lu J, Lv Z, Wang B, Zhang S, Xu P Biomol Biomed. 2024; 25(2):346-359.

PMID: 39388705 PMC: 11734830. DOI: 10.17305/bb.2024.11197.


Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives.

Huang J, Yan Z, Song Y, Chen T Pharmaceutics. 2024; 16(5).

PMID: 38794313 PMC: 11125447. DOI: 10.3390/pharmaceutics16050651.


Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?.

Bardakov S, Tsargush V, Carlier P, Duc T, Emelin A, Polushin A Acta Myol. 2023; 41(4):178-187.

PMID: 36793652 PMC: 9896596. DOI: 10.36185/2532-1900-082.


Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case-Control study.

Stascheit F, Aigner A, Mergenthaler P, Hotter B, Hoffmann S, Lehnerer S Front Neurol. 2023; 13:1056322.

PMID: 36712429 PMC: 9875128. DOI: 10.3389/fneur.2022.1056322.


References
1.
Martignago S, Fanin M, Albertini E, Pegoraro E, Angelini C . Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol. 2009; 35(1):103-10. DOI: 10.1111/j.1365-2990.2008.00965.x. View

2.
Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C . Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007; 68(8):609-11. DOI: 10.1212/01.wnl.0000254620.45529.97. View

3.
Nemoto Y, Kuwabara S, Misawa S, Kawaguchi N, Hattori T, Takamori M . Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005; 76(5):714-8. PMC: 1739635. DOI: 10.1136/jnnp.2004.043125. View

4.
Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y . Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005; 57(2):289-93. DOI: 10.1002/ana.20341. View

5.
Stickler D, Massey J, Sanders D . MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. 2005; 116(9):2065-8. DOI: 10.1016/j.clinph.2005.06.003. View